arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Neuphoria Therapeutics Inc.

NEUP

$3.94 0.00 (+0.13%) at close

4 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Neuphoria Therapeutics Inc. faces fundamental challenges with weakness in Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.4M

Dividend Yield —

Revenue Growth —

Op. Margin -7.2%

ROIC -2.6% ↗

FCF / Share $0.05 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield 1.2%

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-369.63K

↑ +97.6% —

FCF / Share Free cash flow per share

$0.05

↑ +682.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↑

Financial Health ↑

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
EPS Growth YoY (%)	-2200.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	50.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	97.6% Excellent Excellent Year-over-year change in net income	27.5% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	18.1% Good Good Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
Operating Margin (%) (%)	-7.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-148%)	—	—	—
Effective Tax Rate (%) (%)	55.9% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-2.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-120%)	—	—	—
FCF Margin (%) (%)	0.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	-0.21x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
Return on Invested Capital (%)	-2.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-101.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-99.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-3.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-64.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-77.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-1.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-113%)	-88.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-691%)	-97.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-748%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
Interest Coverage (x)	-64.77x Weak Weak Operating income divided by interest expense Optimal: > 5x	-567.72x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-14.21M	$-12.61M	$-12.10M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
Revenue per Share (USD)	$9.64	—	—	—
Basic EPS, GAAP (USD)	$-0.23	$-0.01	$-0.02	—
Free Cash Flow per Share (USD)	$0.05	$-0.01	$-0.01	—
Book Value per Share (USD)	$9.60	$0.01	$0.01	—
Tangible Book Value per Share (USD)	$2.81	$0.00	$0.00	—
Basic Weighted Avg Shares (shares)	1.62M	1.80B	1.47B	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
Working Capital (USD)	$10.82M	$9.36M	$10.59M	—
Total Equity (USD)	$19.00M	$17.49M	$22.01M	$39.23M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$15.65M	—	—	—
Depreciation Expense (USD)	—	$100.00K	$100.00K	—
Net Income, GAAP (USD)	$-369.63K	$-15.49M	$-21.38M	—
Operating Cash Flow (USD)	$77.23K	$-14.68M	$-14.64M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 13 quarters

Neuphoria Therapeutics Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NEUP with peers